KAIZA Bio Private Limited is an agritech and biotechnology startup focused on developing sustainable bio-fermentation technologies for high-value biopharmaceuticals and environmental biotechnology. The company combines plant tissue culture, microbial fermentation, and synthetic biology to develop innovative, eco-friendly solutions for agriculture and healthcare.
At AIC-UASB, KAIZA Bio is incubated for the sustainable production of the anti-cancer drug Taxol (Paclitaxel) using endophytic fungi and plant cell culture-based bio-fermentation. This innovative approach aims to reduce dependence on natural plant sources while enabling scalable, cost-effective, and environmentally sustainable production. The startup also explores advanced bioprocess engineering and digital technologies to strengthen the agricultural biotechnology value chain.
